Patients younger than 40years old and older than 70years old affected by ER(-)/PR(-)/HER2(-) breast cancer have low survival rates: Results of a mono-institutional retrospective analysis

Pietro Sanpaolo, Viviana Barbieri, Domenico Genovesi, Vincenzo Fusco, Giampiero Ausili Cèfaro, Riccardo A. Audisio

Research output: Contribution to journalArticle

Abstract

Objective: The aim of this study is to evaluate the survival and tumor characteristics, including breast cancer phenotypes, of older patients affected by breast cancer and compare these results with those of younger patients. Materials and Methods: Data of 890 patients were analyzed. Patient characteristics and outcomes were evaluated among women aged. ≤ 40 vs 41-50 vs 51-60 vs 61-70 vs > 70. years old. Results: Patients > 70. years old had more frequently a HER2(+) breast cancer phenotype and positive axillary nodes and had lower breast cancer specific survival and distant metastases free survival rates. When analysed for ER(-)/PR(-)/HER2(-) phenotype, younger and older patients had lower survival compared with other age subgroups. Conclusions: In our study, patients younger than 40. years old and older than 70. years affected by ER(-)/PR(-)/HER2(-) breast cancer have lower survival. Considering that there is no common behavior on how to treat older patients affected by this particular breast cancer phenotype, there is an increasing need to enroll older patients in clinical trials in order to realize tailored standards of care.

Original languageEnglish
Pages (from-to)312-319
Number of pages8
JournalJournal of Geriatric Oncology
Volume3
Issue number4
DOIs
Publication statusPublished - Oct 2012

Keywords

  • Adjuvant radiotherapy
  • Breast cancer subtypes
  • Breast-conserving surgery
  • Estrogen receptor
  • HER-2
  • Older patients
  • Progesterone receptor

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Oncology

Fingerprint Dive into the research topics of 'Patients younger than 40years old and older than 70years old affected by ER(-)/PR(-)/HER2(-) breast cancer have low survival rates: Results of a mono-institutional retrospective analysis'. Together they form a unique fingerprint.

  • Cite this